Efficacy and pharmacokinetics of midazolam during sedation in patients with severe cardiopulmonary bypass

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100044020

Enrollment

Unknown

Registered

2021-03-06

Start date

2021-04-01

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patient in severe condition

Interventions

General critical patients group:Nil

ECMO group:NIl

CRRT group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) The age is 18-80 years old; 2) Patients who need sedation and have no contraindication of sedative drugs in ICU; 3) Patients in ECMO group need continuous ECMO treatment for more than 48 hours, and patients in CRRT group need continuous CRRT treatment for more than 16 hours.

Exclusion criteria

Exclusion criteria: 1. Allergic to midazolam, propofol, or dexmedetomidine; 2. Pregnant or lactating; 3. Patients with irreversible injury of central nervous system and unable to determine sedation level; 4. The patient's family members did not sign the informed consent.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics;	—

Countries

China

Contacts

Public ContactQinYong Weng

Department of Critical Care Medicine, Union Hospital Affiliated to Fujian Medical University

Jeromesuper@126.com+86 13365910557

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026